Stocks Health care STOK
NASDAQ · Health careStoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. brought in $27.6M of revenue over the twelve months to June 30, 2026, down 86.2% from a year earlier. It posted a net loss of $207.9M. Operating cash flow minus capital spending left $44.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $110M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What Stoke Therapeutics, Inc. does
Stoke Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker STOK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $184.4M | -$6.9M | -$0.12 | $44.9M |
| 2024 | $36.6M | -$89M | -$1.65 | -$87.1M |
| 2023 | $8.8M | -$104.7M | -$2.38 | -$82.7M |
| 2022 | $12.4M | -$101.1M | -$2.60 | -$35.8M |
| 2021 | n/a | -$85.8M | -$2.34 | -$68.1M |
| 2020 | n/a | -$52.2M | -$1.56 | -$43.3M |
Latest SEC filings
What Stoke Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Other event 8-K
- August 3, 2026
- August 3, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- June 30, 2026
Questions about STOK
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker STOK.
Is Stoke Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $207.9M on revenue of $27.6M.
How much revenue does Stoke Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Stoke Therapeutics, Inc. reported revenue of $27.6M. That is 86.2% less than a year earlier.
When did Stoke Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 25, 2026.
Similar companies
Follow STOK
Get an email when Stoke Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow STOK: get an email when it filesWhere the numbers come from
Financial figures are the values Stoke Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.